| WB | 1/500 - 1/2000 | Human,Monkey |
| IF | 咨询技术 | Human,Monkey |
| IHC | 1/200 - 1/1000 | Human,Monkey |
| ICC | 1/200 - 1/1000 | Human,Monkey |
| FCM | 咨询技术 | Human,Monkey |
| Elisa | 1/10000 | Human,Monkey |
| Aliases | BEST 2 antibody; FLJ20132 antibody; Vitelliform macular dystrophy 2 homolog antibody |
| Entrez GeneID | 54831 |
| WB Predicted band size | Calculated MW: 57 kDa; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse,Rat |
| Immunogen | Synthetic Peptide of BEST2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于BTK抗体的3篇代表性文献(示例仅供参考，具体文献需通过学术数据库获取)：
1. **文献名称**：Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
**作者**：Byrd JC, et al.
**摘要**：该研究报道了BTK抑制剂伊布替尼(Ibrutinib)在复发/难治性慢性淋巴细胞白血病(CLL)患者中的显著疗效，通过抑制BTK信号通路阻断B细胞恶性增殖，总缓解率达70%以上。
2. **文献名称**：Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
**作者**：Woyach JA, et al.
**摘要**：探讨了BTK抑制剂临床应用中出现的耐药机制，包括BTK蛋白突变(如C481S)和替代信号通路激活，为优化治疗策略提供依据。
3. **文献名称**：BTK Inhibition in Autoimmunity and Alloimmunity
**作者**：Haselmayer P, et al.
**摘要**：综述了BTK抑制剂在类风湿性关节炎、系统性红斑狼疮等自身免疫疾病中的潜在应用，通过调节B细胞和巨噬细胞功能抑制炎症反应。
4. **文献名称**：Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
**作者**：Honigberg LA, et al.
**摘要**：首次报道了共价结合型BTK抑制剂的设计与筛选，阐明其通过靶向BTK活性位点的Cys481实现高选择性抑制，奠定伊布替尼等药物的研发基础。
---
**提示**：建议通过PubMed或Web of Science检索关键词“BTK inhibitor”或“BTK antibody”获取最新文献。部分研究可能同时涉及治疗性抗体(如抗CD20单抗联合BTK抑制剂)和BTK靶向小分子药物，需根据需求筛选。
Bruton's tyrosine kinase (BTK) is a cytoplasmic enzyme belonging to the Tec family of non-receptor tyrosine kinases. It plays a critical role in B-cell development, differentiation, and signaling through the B-cell receptor (BCR). BTK activation is essential for pathways regulating proliferation, survival, and antigen response in B-cells. Mutations in the BTK gene cause X-linked agammaglobulinemia (XLA), a primary immunodeficiency characterized by absent or reduced mature B-cells and immunoglobulins.
In oncology, BTK gained attention due to its constitutive activation in B-cell malignancies like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia. This dysregulation promotes malignant cell survival and proliferation. BTK inhibitors, such as ibrutinib and acalabrutinib, emerged as breakthrough therapies by covalently binding to BTK's active site, blocking downstream signaling pathways like NF-κB and PI3K/AKT.
Research continues to explore BTK's role in autoimmune diseases (e.g., rheumatoid arthritis) and its involvement in macrophage/Fcγ receptor signaling. While BTK inhibitors show high efficacy, challenges remain regarding resistance mechanisms and off-target effects. Next-generation reversible inhibitors and combination therapies are under investigation to improve treatment outcomes and minimize adverse events.
×
